NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018

• DOI: 10.6004/jnccn.2018.0007
• Publication Date: 2018-02-12T11:09:39Z
• Authors: Steven M. Horwitz; Stephen M. Ansell; Weiyun Z. Ai; Jeffrey Barnes; Stefan K. Barta; Michael Choi; Mark W. Clemens; Ahmet Dogan; John P. Greer; Ahmad Halwani; Bradley M. Haverkos; Richard T. Hoppe; Eric Jacobsen; Deepa Jagadeesh; Youn H. Kim; Matthew A. Lunning; Amitkumar Mehta; Neha Mehta-Shah; Yahurio Oki; Elise A. Olsen; Barbara Pro; Saurabh A. Rajguru; Satish Shanbhag; Andrei Shustov; Lubomir Sokol; Pallawi Torka; Ryan Wilcox; Basem William; Jasmine Zain; Mary A. Dwyer; Hema Sundar
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Disease Management; Humans; Lymphoma, T-Cell; 3. Good health

Natural killer (NK)/T-cell lymphomas are a rare and distinct subtype of non-Hodgkin's lymphomas. NK/T-cell predominantly extranodal most these nasal type, often localized to the upper aerodigestive tract. Because (ENKL) malignancies, randomized trials comparing different regimens have not been conducted date standard therapy has yet established for patients. These NCCN Guidelines Insights discuss recommendations diagnosis management patients with ENKL as outlined in T-Cell Lymphomas.